Biological Features of Leukaemic Cells Associated with Autonomous Growth and Reduced Survival in Acute Myeloblastic Leukaemia

References

• Zittoun R., Jehn U., Fiere D., et al. Alternating V Repeated post remission treatment in adult acute myelogenous leukemia. A randomised phase HI study (AML6) of the EORTC leukemia Co-operative group. Blood 1989; 73: 896–906
   PubMed Web of Science ®Google Scholar
• Estey E., Smith T., Keating M., McCredie K., Gehan E., Freirich B. Prediction of survival during induction therapy in patients with newly diagnosed AML. Leukemia 1989; 3: 257–263
   PubMed Web of Science ®Google Scholar
• Buick R., Till J. E., McCulloch E. A. Colony assay for proliferative blasts progenitor cells circulating in myeloblastic leukaemia. Lancet 1977; 1: 862–863
   PubMed Web of Science ®Google Scholar
• Reilly I. A. G., Kozlowski R., Russell N. H. Heterogenous mechanisms of autocrine growth of AML blasts. Br. J. Haematol. 1989; 11: 363–369
   Web of Science ®Google Scholar
• Reilly I. A. G., Kozlowski R., Russell N. H. The Role of cell contact and autostimulating soluble factors in the proliferation of blast cells in acute myeloblastic leukemia. Leukemia 1988; 3: 145–150
   Web of Science ®Google Scholar
• Young D. C., Griffin J. D. Autocrine secretion of GM-CSF in acute myeloblastic leukaemia. Blood 1986; 68: 1178–1181
   PubMed Web of Science ®Google Scholar
• Young D. C., Wagner K., Griffin J. D. Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J. Clin. Invest. 1989; 79: 200–206
   Google Scholar
• Oster W., Cicco N. A., Klein H., et al. Participation of cytokines interleukin-6, tumour necrosis factor alpha and interleukin-1-β secreting acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J. Clin. Invest. 1989; 84: 451–457
   PubMed Web of Science ®Google Scholar
• Russell N. H. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev. 1992; 6: 149–156
   PubMed Web of Science ®Google Scholar
• Bradbury D., Rogers S., Reilly I. A. G., Kozlowski R., Russell N. H. Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1β in the autonomous growth of acute myeloblastic leukemia cells-studies using purified CD34-positive cells. Leukemia 1992; 6: 562–566
   PubMed Web of Science ®Google Scholar
• Park L. S., Waldron P. B., Friend D., et al. GM-CSF and G-CSF receptors on cell lines and primary leukemia cells receptor heterogeneity and relationship to growth factor responsiveness. Blood 1989; 74: 56–65
   PubMed Web of Science ®Google Scholar
• Budel L. M., Touw I., Delwel R., Clark S. C., Lowenberg B. Interleukin-3 and granulocyte macrophage colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to proliferative response. Blood 1989; 74: 565–571
   PubMed Web of Science ®Google Scholar
• Hunter A. E., Rogers S. Y., Roberts I. A. G., Barrett A. J., Russell N. H. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 1993; 82: 899–903
   PubMed Web of Science ®Google Scholar
• Lowenberg B., Van Potten W. L. J., Touw I., Delwel R., Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult myeloid leukemia. N. Engl. J. Med. 1993; 32: 614–619
   Web of Science ®Google Scholar
• Keating M. J., Smith T. L., Kantarjian H., et al. Cytogenetic pattern in acute myelogenous leukemia. A major reproducible determinant of outcome. Leukemia 1988; 2: 403–412
   PubMed Web of Science ®Google Scholar
• Spom M. B., Roberts A. B. Autocrine growth factors and cancer. Nature 1985; 313: 745–747
   PubMed Web of Science ®Google Scholar
• Zhu Y. M., Bradbury D., Russell N. H. Decreased retinoblastoma protein expression in acute myeloblastic leukaemia is associated with the autonomous proliferation of clonogenic blasts. Br. J. Haematol. 1994; 86: 533–539
   PubMed Web of Science ®Google Scholar
• Zhu Y. M., Bradbury D., Russell N. H. Expression of different conformation of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. Br. J. Cancer 1993; 68: 851–855
   PubMed Web of Science ®Google Scholar
• Kornblau S. M., Xu H.-J., del Giglio A., et al. Clinical implications for decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res. 1992; 52: 4587–4590
   PubMed Web of Science ®Google Scholar
• Fenaux P., Preudhomme C., Quiquandon I., et al. Mutations of the p53 gene in acute myeloid leukaemia. Br. J. Haematol. 1992; 80: 178–183
   PubMed Web of Science ®Google Scholar
• Dive C., Hickman J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death. Br. J. Cancer 1991; 64: 192–196
   PubMed Web of Science ®Google Scholar
• Lotem J., Sachs L. Haematopoietic cytokines inhibit apoptosis induced by transforming growth factor Bi cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750–1757
   PubMed Web of Science ®Google Scholar
• Bradbury D., Zhu Y.-M., Russell N. H. Regulation of bcl-2 expression and apoptosis in acute myeloblastic leukemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 1994; 8: 786–791
   PubMed Web of Science ®Google Scholar
• Williams G. T., Smith C. A., Spooncer E., Dexter T. M., Taylor D. R. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76–79
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Schmitt E. M., Smith S. W., Jacks B. A., Osborne T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847–849
   PubMed Web of Science ®Google Scholar
• Clarke A. R., Purdie C. A., Harrison D. J., et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849–852
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Riley H. E., Jacks T., Houseman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 1993; 74: 957–967
   PubMed Web of Science ®Google Scholar
• Sugimoto K., Toyoshima H., Sakai R., et al. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153–1157
   PubMed Web of Science ®Google Scholar
• Wada H., Asada M., Nakazawa S., et al. Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 1993; 8: 53–59
   Web of Science ®Google Scholar
• Hockenbery D., Nunez G., Milliman C., Schreiber R. D., Korsmeyer S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–336
   PubMed Web of Science ®Google Scholar
• Vaux D. L., Cory S., Adams J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalise pre-B-cells. Nature 1988; 335: 440–446
   PubMed Web of Science ®Google Scholar
• Miyashitu T., Reed J. C. Bcl-2 Oncoprotein blocks chemotherapy-induced apoptosis in a human leukemic cell line. Blood 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar
• Delia D., Aiello A., Soligo D., et al. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992; 79: 1291–1298
   PubMed Web of Science ®Google Scholar
• Danescu M., Rubio-Trujillo M., Biron G., Dron D., De-Lespesse G., Scarfati M. Interleukin-4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates bcl-2 expression. J. Exp. Med. 1992; 176: 1319–1325
   PubMed Web of Science ®Google Scholar
• Lotem J., Sachs L. Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiated competent and defective myeloid leukaemic cells. Cell Growth Differ. 1993; 4: 31–49
   PubMedGoogle Scholar
• Lotem J., Cragoe E. J., Sachs L. Rescue from programmed cell death in leukemic and normal myeloid cells. Blood 1991; 78: 953–960
   PubMed Web of Science ®Google Scholar
• Campos L., Sabiolo J. P., Rouault O., et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091–3096
   PubMed Web of Science ®Google Scholar
• Estey E., Thau P. F., Kantarjian H., et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony stimulating factor (GM-CSF) before and during continuous infusion high-dose Ara-C and dau-norubicin: Comparison to patients treated without GM-CSF. Blood 1992; 79: 2246–2255
   PubMed Web of Science ®Google Scholar